These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24361964)

  • 1. Hypoglycosylation of dystroglycan due to T192M mutation: a molecular insight behind the fact.
    Bhattacharya S; Das A; Ghosh S; Dasgupta R; Bagchi A
    Gene; 2014 Mar; 537(1):108-14. PubMed ID: 24361964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-silico structural analysis of E509K mutation in LARGE and T192M mutation in Alpha Dystroglycan in the inhibition of glycosylation of Alpha Dystroglycan by LARGE.
    Bhattacharya S; Das A; Bagchi A
    Comput Biol Chem; 2016 Oct; 64():313-321. PubMed ID: 27565399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy.
    Dai Y; Liang S; Dong X; Zhao Y; Ren H; Guan Y; Yin H; Li C; Chen L; Cui L; Banerjee S
    J Cell Mol Med; 2019 Feb; 23(2):811-818. PubMed ID: 30450679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limb girdle muscular dystrophy type 2I: No correlation between clinical severity, histopathology and glycosylated α-dystroglycan levels in patients homozygous for common FKRP mutation.
    Alhamidi M; Brox V; Stensland E; Liset M; Lindal S; Nilssen Ø
    Neuromuscul Disord; 2017 Jul; 27(7):619-626. PubMed ID: 28479227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Structure of the T190M Mutant of Murine α-Dystroglycan at High Resolution: Insight into the Molecular Basis of a Primary Dystroglycanopathy.
    Bozzi M; Cassetta A; Covaceuszach S; Bigotti MG; Bannister S; Hübner W; Sciandra F; Lamba D; Brancaccio A
    PLoS One; 2015; 10(5):e0124277. PubMed ID: 25932631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fourth case of POMT2-related limb girdle muscle dystrophy with mild reduction of α-dystroglycan glycosylation.
    Saredi S; Gibertini S; Ardissone A; Fusco I; Zanotti S; Blasevich F; Morandi L; Moroni I; Mora M
    Eur J Paediatr Neurol; 2014 May; 18(3):404-8. PubMed ID: 24183756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α-dystroglycan.
    Carss KJ; Stevens E; Foley AR; Cirak S; Riemersma M; Torelli S; Hoischen A; Willer T; van Scherpenzeel M; Moore SA; Messina S; Bertini E; Bönnemann CG; Abdenur JE; Grosmann CM; Kesari A; Punetha J; Quinlivan R; Waddell LB; Young HK; Wraige E; Yau S; Brodd L; Feng L; Sewry C; MacArthur DG; North KN; Hoffman E; Stemple DL; Hurles ME; van Bokhoven H; Campbell KP; Lefeber DJ; ; Lin YY; Muntoni F
    Am J Hum Genet; 2013 Jul; 93(1):29-41. PubMed ID: 23768512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Dystroglycan hypoglycosylation affects cell migration by influencing β-dystroglycan membrane clustering and filopodia length: A multiscale confocal microscopy analysis.
    Palmieri V; Bozzi M; Signorino G; Papi M; De Spirito M; Brancaccio A; Maulucci G; Sciandra F
    Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2182-2191. PubMed ID: 28572004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SEA domain proteolysis determines the functional composition of dystroglycan.
    Akhavan A; Crivelli SN; Singh M; Lingappa VR; Muschler JL
    FASEB J; 2008 Feb; 22(2):612-21. PubMed ID: 17905726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.
    Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T
    Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein in some, but not all, dystroglycanopathy patients.
    Humphrey EL; Lacey E; Le LT; Feng L; Sciandra F; Morris CR; Hewitt JE; Holt I; Brancaccio A; Barresi R; Sewry CA; Brown SC; Morris GE
    Neuromuscul Disord; 2015 Jan; 25(1):32-42. PubMed ID: 25387694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant glycosylation of alpha-dystroglycan causes defective binding of laminin in the muscle of chicken muscular dystrophy.
    Saito F; Blank M; Schröder J; Manya H; Shimizu T; Campbell KP; Endo T; Mizutani M; Kröger S; Matsumura K
    FEBS Lett; 2005 Apr; 579(11):2359-63. PubMed ID: 15848172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HNK-1 sulfotransferase-dependent sulfation regulating laminin-binding glycans occurs in the post-phosphoryl moiety on α-dystroglycan.
    Nakagawa N; Takematsu H; Oka S
    Glycobiology; 2013 Sep; 23(9):1066-74. PubMed ID: 23723439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent Advances in α-dystroglycanopathy].
    Kuga A; Kanagawa M; Toda T
    Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan.
    Stevens E; Carss KJ; Cirak S; Foley AR; Torelli S; Willer T; Tambunan DE; Yau S; Brodd L; Sewry CA; Feng L; Haliloglu G; Orhan D; Dobyns WB; Enns GM; Manning M; Krause A; Salih MA; Walsh CA; Hurles M; Campbell KP; Manzini MC; ; Stemple D; Lin YY; Muntoni F
    Am J Hum Genet; 2013 Mar; 92(3):354-65. PubMed ID: 23453667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A second Ig-like domain identified in dystroglycan by molecular modelling and dynamics.
    De Rosa MC; Pirolli D; Bozzi M; Sciandra F; Giardina B; Brancaccio A
    J Mol Graph Model; 2011 Aug; 29(8):1015-24. PubMed ID: 21605994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.
    Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T
    J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy.
    Larson AA; Baker PR; Milev MP; Press CA; Sokol RJ; Cox MO; Lekostaj JK; Stence AA; Bossler AD; Mueller JM; Prematilake K; Tadjo TF; Williams CA; Sacher M; Moore SA
    Skelet Muscle; 2018 May; 8(1):17. PubMed ID: 29855340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. POGLUT1 biallelic mutations cause myopathy with reduced satellite cells, α-dystroglycan hypoglycosylation and a distinctive radiological pattern.
    Servián-Morilla E; Cabrera-Serrano M; Johnson K; Pandey A; Ito A; Rivas E; Chamova T; Muelas N; Mongini T; Nafissi S; Claeys KG; Grewal RP; Takeuchi M; Hao H; Bönnemann C; Lopes Abath Neto O; Medne L; Brandsema J; Töpf A; Taneva A; Vilchez JJ; Tournev I; Haltiwanger RS; Takeuchi H; Jafar-Nejad H; Straub V; Paradas C
    Acta Neuropathol; 2020 Mar; 139(3):565-582. PubMed ID: 31897643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.